Christopher H Wright Net Worth

The estimated Net Worth of Christopher H Wright is at least $265 Thousand dollars as of 28 November 2018. Christopher Wright owns over 10,000 units of Misonix Inc stock worth over $265,400 and over the last 9 years Christopher sold MSON stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Christopher Wright MSON stock SEC Form 4 insiders trading

Christopher has made over 1 trades of the Misonix Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Christopher exercised 10,000 units of MSON stock worth $76,700 on 28 November 2018.

The largest trade Christopher's ever made was exercising 10,000 units of Misonix Inc stock on 28 November 2018 worth over $76,700. On average, Christopher trades about 1,429 units every 0 days since 2015. As of 28 November 2018 Christopher still owns at least 10,000 units of Misonix Inc stock.

You can see the complete history of Christopher Wright stock trades at the bottom of the page.

What's Christopher Wright's mailing address?

Christopher's mailing address filed with the SEC is 1938 New Hwy, Farmingdale, NY 11735, USA.

Insiders trading at Misonix Inc

Over the last 21 years, insiders at Misonix Inc have traded over $4,371,211 worth of Misonix Inc stock and bought 1,536,334 units worth $6,620,934 . The most active insiders traders include Stavros G. Vizirgianakis, Gary Gelman, and Michael A Jr Mcmanus. On average, Misonix Inc executives and independent directors trade stock every 29 days with the average trade being worth of $378,885. The most recent stock trade was executed by Sharon W Klugewicz on 20 May 2020, trading 825 units of MSON stock currently worth $10,032.

What does Misonix Inc do?

Misonix, Inc. is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company's history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients.

Complete history of Christopher Wright stock trades at Misonix Inc

Misonix Inc executives and stock owners

Misonix Inc executives and other stock owners filed with the SEC include:

• Stavros Vizirgianakis,
  President, Chief Executive Officer, Director
• Charles Miner,
  Independent Director
• Paul LaViolette,
  Independent Chairman of the Board
• T Guy Minetti,
  Director
• Patrick A Mc Brayer,
  Director
• John Gildea,
  Director
• Thomas M Patton,
  Director
• Michael L Consilvio,
  VP - Marketing
• Richard A Zaremba,
  Vice President and CFO
• John Joseph Salerno,
  VP, Quality & Regulatory
• Howard Alliger,
  Director
• Daniel Voic,
  VP-R&D and Engineering
• Joseph J Brennan,
  Vice President, Operations
• Gary Gelman,
  10% owner
• Michael A Jr Mcmanus,
  President, CEO
• Michael Koby,
  Director
• Christopher H Wright,
  Vice President - U.S. Sales
• Capital Management, Llc1315...,
  
• Gwendolyn A Watanabe,
  Director
• Jonathan Jay Waggoner,
  SVP, Wound Sales
• Thomas F Oneill,
  Director
• Frank Napoli,
  VP, Operations
• Michael C Ryan,
  SVP, Medical Division
• W Paul Constantine,
  SVP, Strat. Plan. & New Prod.
• Kenneth Coviello,
  V.P - Medical Devices
• Ronald Manna,
  VP-New Prod. Dev. & Reg. Aff.
• Bernhard Berger,
  VP-Industrial/Scientific Prod.
• Allan Richard Staley,
  President
• Linwood A. Staub,
  Sr. VP Wound
• Robert S Ludecker,
  SVP, Global Sales - Marketing
• Joseph P Dwyer,
  Chief Financial Officer
• Pat Beyer,
  Director
• Sharon W Klugewicz,
  Chief Operating Officer